New cell therapy targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-phase study tests a personalized cell therapy for people with advanced solid tumors that have specific KRAS mutations. The treatment uses a patient's own immune cells, engineered to recognize and attack cancer cells. The main goal is to check safety and find the right …
Phase: PHASE1 • Sponsor: Ting Deng • Aim: Disease control
Last updated May 11, 2026 20:51 UTC